In this session of her SEC deposition (recorded August 23, 2017), Theranos founder and former CEO Elizabeth Holmes is questioned in detail regarding regulatory dealings, internal executive communications, commercial partnerships, and claims made to investors. Key topics covered include: Interactions with the FDA: Regulatory meetings, internal review processes, note-taking practices, and the decision to stop using the Nanotainer tube following federal inspections. Internal Communications with Sunny Balwani: Scrutiny of text messages concerning regulatory strategy, laboratory vs. fingerstick marketing, and responses to the FDA. The Walgreens Partnership: Negotiations, expansion projections, the $100M innovation fee accounting/refund provisions, and Walgreens’ reaction to the October 2015 Wall Street Journal investigation. Military & Defense Claims: Clarification regarding contracts, revenue, and whether Theranos devices were ever actually deployed in the battlefield, medevac helicopters, or with commands such as SOCOM, AFRICOM, and CENTCOM. Pharmaceutical Partner Reports: Examination of third-party vs. internally prepared reports (Pfizer, GSK, Schering-Plough) distributed in prospective investor packets. Listen To Hidden Killers Podcast ANYWHERE! Listen Here: https://linktr.ee/hiddenkillers Join Our SubStack For AD-FREE ADVANCE EPISODES & EXTRAS!: https://hiddenkillers.substack.com/ Instagram https://www.instagram.com/hiddenkillerspod/ Facebook https://www.facebook.com/hiddenkillerspod/ Tik-Tok https://www.tiktok.com/@hiddenkillerspod X Twitter https://x.com/tonybpod This publication contains commentary and opinion based on publicly available information. All individuals are presumed innocent until proven guilty in a court of law. Nothing published here should be taken as a statement of fact, health or legal advice.